PMID- 37346799
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230701
IS  - 0038-0121 (Print)
IS  - 0038-0121 (Electronic)
IS  - 0038-0121 (Linking)
VI  - 88
DP  - 2023 Aug
TI  - Evaluation of the treatment options for COVID-19 patients using generalized 
      hesitant fuzzy- multi criteria decision making techniques.
PG  - 101614
LID - 10.1016/j.seps.2023.101614 [doi]
AB  - The breakout of the pandemic COVID-19 has affected numerous countries and 
      territories worldwide. As COVID-19 specific medicines yet to be invented, at 
      present the treatment is case specific, hence identification and evaluation of 
      different prevalent treatment options based on various criteria and attributes 
      are very important not only from the point of view of present pandemic but also 
      for futuristic pandemic preparedness. The present study focuses on identifying, 
      evaluation and ranking of treatment options using Multi Criteria Decision Making 
      (MCDM). In this regard, the existing literature, doctors and scientist were 
      interviewed to know the current treatment options in vogue and the scale of their 
      importance with respect to the criteria. The criteria taken are side effect, 
      regime cost, treatment duration, plasma stability, plasma turnover, time of 
      suppression, ease of application, drug-drug interaction, compliance, fever, 
      pneumonia, intensive care, organ failure, macrophage activation syndrome, 
      hemophagocytic syndrome, pregnancy, kidney problem, age. This study extended 
      Hesitant Fuzzy Set (HFS) to Generalized Hesitant Fuzzy Sets (GHFS). Generalized 
      Hesitant Pentagonal Fuzzy Number (GHPFN) is developed. The properties of GHPFN 
      are demonstrated. Two types of GHPFN has been described. The GHPFN (2nd type) 
      along with MCDM tool Technique for Order Preference by Similarity to Ideal 
      Solution (TOPSIS) has been applied to rank the treatment options. The result of 
      the study ranked 'Hydroxychloroquine' as the first alternative followed by, 
      'Plasma Exchange', 'Tocilizumab', 'Remdesivir' and 'Favipravir'. To check the 
      robustness and steadiness of the proposed methodology, comparative analysis and 
      sensitivity analysis has been conducted.
CI  - (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Nandi, Sandip
AU  - Nandi S
AD  - Institute of Business Management & Research, Kolkata, WB, India.
FAU - Granata, Giuseppe
AU  - Granata G
AD  - Department of Economics University Mercatorum of Rome, Italy.
FAU - Jana, Subrata
AU  - Jana S
AD  - Department of Mathematics, Jadavpur University, Kolkata, West Bengal, India.
FAU - Ghorui, Neha
AU  - Ghorui N
AD  - Department of Mathematics, Prasanta Chandra MahalanobisMahavidyalaya, Kolkata, 
      West Bengal, India.
FAU - Mondal, Sankar Prasad
AU  - Mondal SP
AD  - Department of Applied Science, MaulanaAbulKalam Azad University of Technology, 
      Haringhata, West Bengal, India.
FAU - Bhaumik, Moumita
AU  - Bhaumik M
AD  - ICMR-National Institute of Cholera and Enteric Diseases, Beleghata, Kolkata, West 
      Bengal, India.
LA  - eng
PT  - Journal Article
DEP - 20230605
PL  - United States
TA  - Socioecon Plann Sci
JT  - Socio-economic planning sciences
JID - 9877811
PMC - PMC10241491
OTO - NOTNLM
OT  - COVID-19
OT  - GHFS
OT  - GHPFN
OT  - GHPFN (2nd type)
OT  - HFS
OT  - MCDM
OT  - TOPSIS
EDAT- 2023/06/22 13:09
MHDA- 2023/06/22 13:10
PMCR- 2023/06/05
CRDT- 2023/06/22 09:55
PHST- 2022/09/27 00:00 [received]
PHST- 2023/03/16 00:00 [revised]
PHST- 2023/05/13 00:00 [accepted]
PHST- 2023/06/22 13:10 [medline]
PHST- 2023/06/22 13:09 [pubmed]
PHST- 2023/06/22 09:55 [entrez]
PHST- 2023/06/05 00:00 [pmc-release]
AID - S0038-0121(23)00114-3 [pii]
AID - 101614 [pii]
AID - 10.1016/j.seps.2023.101614 [doi]
PST - ppublish
SO  - Socioecon Plann Sci. 2023 Aug;88:101614. doi: 10.1016/j.seps.2023.101614. Epub 
      2023 Jun 5.